国际输血及血液学杂志最新文献

{"title":"One case of hemophilia B combined with FIX inhibitor","authors":"Xuewei Li, Xingxu Wang, Dongjie Zhang, Zhaoyue Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2020.01.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2020.01.009","url":null,"abstract":"Objective \u0000To explore the clinical characteristics and treatment of hemophilia B with coagulation factor FⅨ inhibitor. \u0000 \u0000 \u0000Methods \u0000On February 8, 2018, one case of child with hemophilia B and FⅨ inhibitor who was admitted to First Affiliated Hospital of Soochow University was selected as research subject into this study. The medical history of the children was collected, coagulation function indicators, plasma coagulation factors, coagulation factor inhibitors and other laboratory tests were conducted, And the diagnosis was made based on the results of above tests and gene sequencing. The child were treated with prednisone (15 mg/d) combined with cyclosporine (50 mg/time×2 times/d) and prednisone (15 mg/d) combined with rapamycin (1.5 mg/d). Treatment efficiency was evaluated by relevant laboratory test results of the child. Follow-up was conducted until September 30, 2019. Clinical characteristics, diagnosis, treatment and curative effect of this case were analyzed retrospectively. The procedure of this study was in accordance with the requirements of the revised World Medical Association Declaration of Helsinki in 2013. \u0000 \u0000 \u0000Results \u0000① This child was a 8 years old boy. On February 8, 2018, he was admitted to First Affiliated Hospital of Soochow University due to \" repeated joint pain and swelling for 7 years\" . The child was diagnosed as severe hemophilia B in May, 2010 at local hospital and received treatment with prothrombin complex and recombinant human FⅨ. The titers of FⅨ inhibitors were 3.2 and 6.2 BU/mL in March and April in 2012, respectively. The child suffered from frequent joint bleeding, and the pain was significantly worse than before. ② After admission, result of routine examination of coagulation function showed activated partial thromboplastin time (APTT) was 165.4 s, prothrombin time (PT) was 13.4 s, thrombin time (TT) was 16.6 s, fibrinogen (FIB) was 3.48 g/L, FⅨ∶C was 0.5%, FⅧ∶C was 20%. The results of revealed APTT were 152.7 and 129.6 s immediately and 2 h later, respectively. Antiphospholipid antibodies and lupus anticoagulant were negative. Titer of hemophilia B inhibitor>10 BU/ml. Genetic sequencing displayed a heterozygous mutation of FⅨ c. 7993C>T (p.Arg29X) in exon 2. ③ The child was diagnosed as severe hemophilia B with FⅨ inhibitor. The child did not achieve improvement after treating with prednisone combined with cyclosporine for 3 months. Then the therapy was adjusted to prednisone combined with rapamycin. Although the change of FⅨ inhibitor titer was not obvious, the frequency of joint hemorrhage was decreased after 6 months of treatment. Nine months later, the titer of FⅨ inhibitor was reduced to 50% of that at first diagnosis, with no recurrence of bleeding. The child achieved partial remission (PR). By the end of the follow-up, the child had no joint swelling or pain, and basically returned to normal life and study. \u0000 \u0000 \u0000Conclusions \u0000It should be alert if patients who diagnose as severe hemophilia B and appe","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"43 1","pages":"51-56"},"PeriodicalIF":0.0,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43358911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of clinical characteristics and prognosis factors in patients with angioimmunoblastic T-cell lymphoma","authors":"X. Xia, H. Gu, Baoxia Dong, Tao Zhang, R. Liang, Q. Bai, G. Gao, Lan Yang","doi":"10.3760/CMA.J.ISSN.1673-419X.2020.01.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2020.01.006","url":null,"abstract":"Objective \u0000To investigate the clinical characteristics and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL). \u0000 \u0000 \u0000Methods \u0000From January to December, 2012, a total of 44 AITL patients admitted to Department of Hematology, First Affiliated Hospital of Air Force Medical University were included as study subjects. There were 36 males and 8 females, with age of 18-78 years and median age of 57.5 years. All 44 patients were treated with CHOP (cyclophosphamide + pirarubicin + vincristine + prednisone) regimen, 4 of them were combined with chidamide or bortezomib, 6 of them were combined with autologous hematopoietic stem cell transplantation (auto-HSCT). Clinical characteristics of AITL patients were retrospectively analyzed. Kaplan-Meier method was used to map overall survival (OS) curves of patients treated with and without auto-HSCT. And univariate analysis of OS rate was performed in patients treated without auto-HSCT using Log-rank test. Influencing factors included gender, age, International Prognostic Index (IPI) score, Prognostic Index for peripheral T-cell lymphoma (PIT) score, B symptoms, skin rashes, chest/abdominal cavity effusion, bone marrow involvement, white blood cell count (WBC), hemoglobin (Hb) value, platelet count, serum lactate dehydrogenase (LDH) level, ferritin level, β2-microglobulin (MG) level. Factors with statistical significance in univariate analysis and clinical guiding significance were included in COX proportional hazards regression model for multivariate analysis. The procedure of this study was accordance with the requirement of the revised World Medical Association Declaration of Helsinki in 2008 and 2013. \u0000 \u0000 \u0000Results \u0000① Among 44 AITL patients, 34 cases (77.3%) had B symptoms. Five cases (11.4%) were Ann Arbor Ⅰ-Ⅱ stage, 39 cases (88.6%) were Ⅲ-Ⅳ stage. Twenty cases (45.5%) had Eastern Cooperative Oncology Group, performance status (ECOG-PS) score 60 years, and the difference was statistically significant (χ2=0.139, P=0.023). The 5-year OS rate in patients with serum β2-MG level 60 years (HR=2.716, P=0.031), bone marrow involvement (HR=2.696, P=0.042), serum β2-MG level≥4 mg/L (HR=4.927, P=0.004) were independent risk factors for AITL prognosis. \u0000 \u0000 \u0000Conclusions \u0000Majority of AITL patients are middle-aged and elderly males, often accompanied by skin rash and serous effusion. The disease was first diagnosed late-stage in Ann Arbor. Age>60 years, bone marrow involvement and serum β2-MG level≥4 mg/L, can be used as independent indicators of poor prognosis of patients treated without auto-HSCT. New drugs such as chidamide and bortezomib could improve curative effect of AITL patients. auto-HSCT coukl effectively improve the OS of patients. \u0000 \u0000 \u0000Key words: \u0000Lymphoma; Immunoblastic lymphadenopathy; Drug therapy; Hematopoietic stem cell transplantation; Prognosis; Angioimmunoblastic T-cell lymphoma; Restrospective studies","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"43 1","pages":"27-33"},"PeriodicalIF":0.0,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48800773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and related severe infection of lenalidomide in treatment of patients with multiple myeloma: a Meta-analysis","authors":"L. Fan, Yanping Ma, Meng Zhang, Xiaoyun Gao, Yao Chao","doi":"10.3760/CMA.J.ISSN.1673-419X.2020.01.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2020.01.007","url":null,"abstract":"Objective \u0000To systematically evaluate the efficacy of lenalidomide in the treatment of patients with multiple myeloma(MM) and the risk of related severe infection. \u0000 \u0000 \u0000Methods \u0000PubMed, Embase and Cochrane library controlled trials were searched by computer, to identify research literature of the randomized controlled trials (RCT) of the efficacy of lenalidomide in the treatment of MM and the risk of related severe infection. Patients in study group were treated with lenalidomide or a combination of lenalidomide and dexamethasone, while placebo, dexamethasone or a combination of placebo and dexamethasone were used in control group. Two researchers independently screened the literature according to the literature set in this study and excluded criteria to evaluate the quality of the included literature and extract the data. A Meta-analysis of disease-free survival (PFS), overall survival (OS), incidence of severe infection, incidence of severe respiratory tract infection, and RR of severe infection of MM were performed using R3.3.1 software. Modified Jadad scale was used for RCT quality evaluation. \u0000 \u0000 \u0000Results \u0000A total of 7 RCT literatures were included according to the inclusion criteria of this study through literature screening. A total of 4 007 MM patients were enrolled, of whom 2 117 cases were in study group, and 1 890 cases in control group. Seven literatures were high quality RCT. The results of Meta-analysis were as follows. ① Compared with the control group, the 3-years PFS of the study group was significantly prolonged (HR=0.54, 95% CI: 0.36-0.82, P=0.004), but the 3-years OS was not significantly beneficial (HR=0.84, 95% CI: 0.62-1.14, P=0.262). ②The incidence of severe infection in MM patients was 6.67%-21.47%, the overall incidence was 14.01%(95% CI: 11.01%-17.02%). The incidence of respiratory tract severe infection was 46%(95% CI: 27%-65%). Compared with the control group, the RR of related severe infection in study group was increased (RR=1.92, 95% CI: 1.59-2.33, P<0.000 1). \u0000 \u0000 \u0000Conclusions \u0000Although lenalidomide can benefit the PFS of MM patients, it has no significant improvement on the OS of patients.The risk of related severe infection caused by lenalidomide is very high, especially serious respiratory tract infection. \u0000 \u0000 \u0000Key words: \u0000Multiple myeloma; Lenalidomide; Infection; Respiratory tract infections; Meta-Analysis","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"43 1","pages":"34-42"},"PeriodicalIF":0.0,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44998024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prenatal screening and identification of irregular antibodies of erythrocyte blood type in pregnant women","authors":"B. Han, Yuli Zhu","doi":"10.3760/CMA.J.ISSN.1673-419X.2020.01.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2020.01.012","url":null,"abstract":"Objective \u0000To investigate the distribution and characteristics of irregular antibodies of erythrocyte blood type in pregnant women. \u0000 \u0000 \u0000Methods \u0000From January 2016 to June 2018, a total of 130 pregnant women who were identified for irregular antibodies of erythrocyte blood type in Qingdao Blood Center, were selected as the subjects. The age of the pregnant women was 25-42 years, and the median age was 32 years. ABO and Rh blood group identification of pregnant women, and irregular antibody titers of Rh blood group system were determined by test tube method. The screening and identification of irregular antibodies of erythrocyte blood type were used micro-column gel agglutination or tube test method. The procedure followed in this study was in line with the requirements of the revised World Medical Association Declaration of Helsinki in 2013. And informed consents were obtained from all the subjects. \u0000 \u0000 \u0000Results \u0000① Among the 130 pregnant women, there were 44 cases (33.8%) , 48 cases (36.9%) , 27 cases (20.8%) and 11 cases (8.5%) of blood group A、B、O and AB, respectively. And 90 cases (69.2%) were Rh positive and 40 cases (30.8%) were Rh negative blood group. ② Among the serum samples of 130 pregnant women, 71 cases (54.6%) , 28 cases (21.5%), 3 cases (2.3%) and 14 cases (10.8%) were in Rh, MNSs, P and Lewis blood group system respectively, and 4 cases (3.1%) were anti-HI. ③ Among 71 pregnant women who were detected irregular antibodies of Rh blood group system, antibody titer with the highest detection rate was 2, whose detection rate was 26.8% (19/71). One pregnant woman had an antibody titer of 512. Her Rh blood group was Rh negative. And she had previously received RhD positive red blood cells transfusion. \u0000 \u0000 \u0000Conclusions \u0000In Qingdao City, the irregular antibody distribution in pregnant women with positive irregular antibodies of erythrocyte blood type is dominated by the Rh blood system, followed by the MNSs blood system. Prenatal screening and identification of irregular antibodies of erythrocyte blood group in pregnant women is conducive to ensure the safety of pregnant women′s blood transfusion and reducing the risk of hemolytic disease of newborn (HDN). \u0000 \u0000 \u0000Key words: \u0000Blood group antigens; Antibodies; Pregnant woman; Erythroblastosis, fetal; Blood transfusion; Rh-Hr blood-group system; MNSs blood-group system; Irregular antibody","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"43 1","pages":"67-70"},"PeriodicalIF":0.0,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49570010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and problems of chimeric antigen receptor T cell immunotherapy in treatment of hematological malignancies","authors":"Yulin Xu, Yong-xian Hu, Xiangjun Zeng, Xiaohong Yu, He Huang","doi":"10.3760/CMA.J.ISSN.1673-419X.2020.01.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2020.01.001","url":null,"abstract":"Some patients with hematologic malignancies as acute lymphoblastic leukemia (ALL), can achieve complete remission (CR) after chimeric antigen receptor T cell (CAR-T) immunotherapy. However, many constraints still limit the wide application of CAR-T immunotherapy in patients with hematological malignancies and other cancers, especially in patients with solid tumors. The main challenges related to CAR-T immunotherapy include: relapse caused by immune escape of tumor antigens, cytokine release syndrome (CRS), poor survival time in vivo, low infiltration capacity and inactivation of CAR-T in solid tumors, etc.. This article summarizes effects and problems of CAR-T immunotherapy in clinical trials for hematological malignancies, and how to use comprehensive treatment and biotechnology strategies to solve the current problems, in order to improve safety and effectiveness of CAR-T immunotherapy, and expand clinical benefits of CAR-T immunotherapy for patients with different tumors. \u0000 \u0000 \u0000Key words: \u0000Immunotherapy, adoptive; Receptors, chimeric antigen; Hematologic neoplasms; Chimeric antigen receptor-T cell; Solid tumors; Chimeric antigen receptor T cells immunotherapy; Combined modality therapy","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"43 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46375852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of scrapping reasons for apheresis platele consumables used in Chengdu Blood Center","authors":"Lan Ye, Y. Hong","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.007","url":null,"abstract":"Objective \u0000To explore the scrapping reasons for the apheresis platele consumables of 3 different types blood cell separators used in Chengdu Blood Center. \u0000 \u0000 \u0000Methods \u0000From January 2015 to December 2017, a total of 63 782 sets of apheresis platelets consumables used in Chengdu Blood Center and Tianfu Blood Donation House were selected as subjects. Among them, the apheresis platelets consumables of MCS+ , Amicus, Trima Accel blood cell separators were 28 351, 15 482 and 19 949 sets, respectively. Retrospective investigation method was adopted to inquire the material scrapping situation in the resource management of Chengdu Blood Center and Tianfu Blood Donation House, through the Qiao Blood Station Management System. And the scrapping amount and reasons of apheresis platele consumables were counted, and were checked with the scrapping records from Consumables Scrap Statistics in Apheresis Room. Reasons for scrapped of apheresis platele consumables include consumable factors (pipe wrinkles, breakage, leakage, etc.) and collection factors (venipuncture failure, machine fault, chylemia blood, red blood cell overflow, blood donation response, etc.). After the data were verified correctly, the scrapping rates of apheresis platelets consumables were calculated. The scrapping rates of different blood cell separators and different scrapping reasons were compared by chi-square test, respectively. \u0000 \u0000 \u0000Results \u0000① Among the 63 782 sets of apheresis platelets consumables, a total of 900 sets were scrapped, with a scrapping rate of 1.41% (900/63 782). The scrapping rate of MCS+ blood cell separators was 1.83% (518/28 351), which was higher than that of 1.41% (219/15 482) of Amicus and 0.82% (163/19 949) of Trima Accel blood cell separators, and the differences were statistically significant (χ2=239.10, P<0.001; χ2=162.15, P<0.001). ② Among the 900 sets of scrapping apheresis platelets consumables of this study, the scrapping rate due to collection factors was 1.16% (738/63 782), which was higher than that of 0.25% (162/63 782) due to consumables factors, and the difference was statistically significant (χ2=304.28, P<0.001). Among the 738 sets of scrapping apheresis platelets consumables due to collection factors, the scrapping rate of MCS+ blood cell separators was 1.61% (456/28 351), which was higher than that of 0.96% (148/15 482) of Amicus and 0.67% (134/19 949) of Trima Accel blood cell separators, and the differences were statistically significant (χ2=220.79, P<0.001; χ2=164.42, P<0.001). Among the 162 sets of scrapping apheresis platelets consumables due to consumables factors, the scrapping rate of Amicus blood cell separators was 0.46% (71/15 482), which was higher than of 0.22% (62/28 351) of MCS+ and 0.15% (29/19 949) of Trima Accel blood cell separators, and the differences were statistically significant (χ2=19.05, P<0.001; χ2=30.38, P<0.001). ③ Among the 738 sets of scrapping apheresis platelets consumables due to collection factors, venipuncture ","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"502-507"},"PeriodicalIF":0.0,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48545846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress on haploidentical hematopoietic stem cell transplantation","authors":"Yuan-yuan Feng, Jianyong Li","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.008","url":null,"abstract":"Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is a reliable, effective and emerging treatment for hematological malignancies.Due to the difficulty of human leukocyte antigen (HLA) matching between donors and recipients, the One-child policy, and the decrease of HLA-matched sibling donor (MSD) and so on, the donors selection is greatly limited in hematopoietic stem cell transplant(HSCT). This article reviews the new researches on clinical outcomes for different hematological diseases, conditioning regimen and the prophylaxis of graft versus host disease (GVHD) in the context of haplo-HSCT. \u0000 \u0000 \u0000Key words: \u0000Hematopoietic stem cell transplantation; Leukemia; Transplantation conditioning; Graft vs host disease; Haploidentical hematopoietic stem cell transplantation","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"508-513"},"PeriodicalIF":0.0,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41395113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of posaconazole in prophylaxis against invasive fungal infections in patients with hematological malignancies: a Meta-analysis","authors":"K. Tang, Zhiyong Wang, Chunhong Xin, Rui Jing, Yuping Dong, S. Feng","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.006","url":null,"abstract":"Objective \u0000To systematically evaluate the efficacy and safety of posaconazole in prophylaxis against invasive fungal infection (IFI) in patirnts with hematological malignancies. \u0000 \u0000 \u0000Methods \u0000From the date of databases inception to October 2018, English databases, such as PubMed, Web of Science database and others, as well as Chinese databases, such as Wanfang Date Knowledge Service Platform, Weipu Chinese Science and Technology Journal Database, China National Knowledge Infrastructure (CNKI) and Chinese Biomedical Literature Database (CBM) and others were searched to identify research literature of the randomized controlled trials (RCT) of posaconazole in prophylaxis of IFI in patients with hematological malignancies with study group receiving posaconazole and control group receiving other anti-fungal drugs. The two researchers independently screened the literatures according to the inclusion and exclusion criteria of the literatures set in this study, and evaluated the quality of the included literatures and extracted the materials. Efficacy and safety of posaconazole for preventing IFI in patients with hematological malignancies were Meta analyzed with Revman 5.3 software. The main outcome evaluation indexes of effectiveness and safety of posaconazole in preventing IFI of patients with hematological malignancies include: effectiveness indicator (IFI incidence rate), safety indicators (adverse reactions incidence rate and all-cause mortality). \u0000 \u0000 \u0000Results \u0000Through literature screening, a total of 6 RCTs met the inclusion criteria in this study. A total of 1 994 patients with hematological malignancies were included, including 1 057 patients in study group and 937 patients in control group. ① Meta-analysis of posaconzole to prevent the incidence of IFI in patients with hematological malignancies showed that, incidence rate of IFI in study group was lower than that of control group, and the difference was statistically significant (OR=0.37, 95%CI: 0.27-0.51, P<0.0001). Incidence rate of IFI in patients treated with posaconazole was lower than that of patients treated with fluconazole and itraconazole, respectively, and the differences were statistically significant (OR=0.41, 95%CI: 0.27-0.63, P<0.0001; OR=0.31, 95%CI: 0.20-0.49, P<0.0001). There were no statistical significant difference in incidence rate of IFI between patients treated with posaconazole and voriconazole (OR=0.13, 95%CI: 0.01-2.67, P=0.19). ② Meta-analysis on the incidence rate of adverse reactions to prevent IFI by posaconazole showed that, incidence rate of adverse reactions in study group was lower than that in control group, and the difference was statistically significant (OR=0.80, 95%CI: 0.64-0.99, P=0.04). ③ Meta-analysis on all-cause mortality of posaconazole patients for prevention of IFI showed that, all-cause mortality in the study group was lower than that in control group, and the difference was statistically significant (OR=0.71, 95%CI: 0.55-0.91, P=0.007). \u0000 \u0000 \u0000Co","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"494-501"},"PeriodicalIF":0.0,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44640353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on prevention and treatment of invasive fungal diseases in patients with hematological malignancies","authors":"Yuan-Yuan Zhao","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.015","url":null,"abstract":"The incidence of invasive fungal disease (IFD) is high in patients with hematological malignancies, including those with acute myeloid leukemia(AML)/myelodysplastic syndrome(MDS), and those receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). IFD is an important prognostic factor in patients with hematological malignancies. IFD is difficult to diagnose, and the efficacy of treatment is poor. Therefore, antifungal treatment begins with prevention. At present, there are still controversies about the clinical indications, drugs, administration time and efficacy of IFD chemoprevention. This article intends to review the research progress on the epidemiology and risk factors of IFD, as well as the clinical outcomes of antifungal agents for antifungal prophylaxis in patients with hematological malignancies. \u0000 \u0000 \u0000Key words: \u0000Antifungal agents; Hematologic neoplasms; Epidemiologic studies; Chemoprevention; Invasive fungal disease","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"548-553"},"PeriodicalIF":0.0,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42008870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical analysis of chimeric antigen receptor T cells immunotherapy in treatment of one patient with relapsed/refractory primary central nervous system lymphoma","authors":"Huan-xin Zhang, Zhi-ling Yan, Zhenyu Li, Hu-jun Li, Jiang Cao, W. Sang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.002","url":null,"abstract":"Objective \u0000To investigate the indications, complications and prognosis of chimeric antigen receptor T cells (CAR-T) in the treatment of relapsed/refractory primary central nervous system lymphoma (PCNSL). \u0000 \u0000 \u0000Methods \u0000On May 21, 2015, one patient with relapsed/refractory PNCSL admitted to the Department of Hematology, Xuzhou Medical University Affiliated Hospital was selected as the study object. The peripheral blood lymphocytes of the patient were collected by blood cell apheresis, and humanized CD19 and CD20 CAR-T were prepared. CAR is stably expressed in CD3+ T cells via lentiviral vector. On July 27, 2017, the patient received FC regimen of conditioning regimen by fludarabine 30 mg/(m2·d), d-5 to -3, and cyclophosphamide 750 mg/(m2·d), d-5. Humanized CD19 and CD20 CAR-T were transfused with dose of 1×106/kg each, on the first day after conditioning regimen. The clinical features and diagnosis of the patient were summarized by retrospective analysis. This study was in line with World Medical Association Declaration of Helsinki revised in 2013 and informed contents of clinical research and CAR-T immunotherapy were obtained from the subject. \u0000 \u0000 \u0000Results \u0000① The patient was male and 45 years old. In February 2015, the patient appeared headache, dizziness, and blindness in the right eye without obvious incentives. In March 2015, the patient was diagnosed with diffuse large B-cell lymphoma based on his pathology and immunohistochemistry results. In January 2016, the patient achieved unconfirmed complete remission (CRu) after surgical removal of the corpus callosum, radiotherapy, and high-dose radiation therapy. In March 2017, the patient′s primary disease recurred, but the condition was relieved after receiving temozolomide+ high-dose methotrexate(HD-MTX) chemotherapy. ②After 10 d of CAR-T infusion, the patient′s headache symptoms were significantly reduced and the orientation was recovery. Grade 1 cytokine release syndrome(CRS) occurred during treatment. Patient′s symptoms improved after he received symptomatic supportive treatment. After 29, 69 and 116 d of CAR-T transfusion, the results of patient′s head-enhanced MRI showed that the primary lesion continued to shrink. And the patient reached partial remission (PR). After 69 and 116 d of CAR-T transfusion, CAR-T were detected in cerebrospinal fluid flow cytometry of patient. After 154 d of CAR-T transfusion, the patient returned to hospital for treatment, due to \" left limb weakness\" . Re-examination of head-enhanced MRI showed recurrence of primary disease. Then the patient received salvage treatment of high-dose chemotherapy. As of July 2019, the patient was still receiving temozolomide + HD-MTX chemotherapy for maintenance treatment. \u0000 \u0000 \u0000Conclusions \u0000As a new treatment regimen, CAR-T immunotherapy could be used as a salvage bridging treatment in the treatment of patients with relapsed/refractory PCNSL. And it is still necessary to maintain and consolidate the treatment. However, the above co","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"469-475"},"PeriodicalIF":0.0,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44950446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}